Literature DB >> 12445031

Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population.

Maria Burian1, Sabine Grösch, Irmgard Tegeder, Gerd Geisslinger.   

Abstract

AIMS: The aim was to develop a fast detection method for the polymorphic alleles related to impaired CYP2C9-mediated metabolism.
METHODS: CYP2C9 genotypes were identified in 118 DNA samples using real-time PCR (LightCycler) followed by melting curve analysis. All samples were re-tested by validated PCR-RFLP methodology.
RESULTS: The concordance between the two methods was 100% for two variant alleles. The frequencies of CYP2C9*1 (wild type), CYP2C9*2 and CYP2C9*3 (with 95% confidence intervals) were 0.81(0.05), 0.14(0.04) and 0.05(0.03), respectively, and are similar to those observed in other Caucasian populations.
CONCLUSIONS: This assay is simple and rapid and may be used for CYP2C9-genotyping in a clinical setting.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445031      PMCID: PMC1874480          DOI: 10.1046/j.1365-2125.2002.01693.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.

Authors:  J van der Weide; L S Steijns; M J van Weelden; K de Haan
Journal:  Pharmacogenetics       Date:  2001-06

2.  Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication.

Authors:  H Ninomiya; K Mamiya; S Matsuo; I Ieiri; S Higuchi; N Tashiro
Journal:  Ther Drug Monit       Date:  2000-04       Impact factor: 3.681

3.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Authors:  T H Sullivan-Klose; B I Ghanayem; D A Bell; Z Y Zhang; L S Kaminsky; G M Shenfield; J O Miners; D J Birkett; J A Goldstein
Journal:  Pharmacogenetics       Date:  1996-08

4.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Authors:  A E Rettie; L C Wienkers; F J Gonzalez; W F Trager; K R Korzekwa
Journal:  Pharmacogenetics       Date:  1994-02

5.  High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.

Authors:  E García-Martín; C Martínez; J M Ladero; F J Gamito; J A Agúndez
Journal:  Eur J Clin Pharmacol       Date:  2001-04       Impact factor: 2.953

6.  Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.

Authors:  Y R Yoon; J H Shon; M K Kim; Y C Lim; H R Lee; J Y Park; I J Cha; J G Shin
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

7.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

Authors:  M G Scordo; E Aklillu; U Yasar; M L Dahl; E Spina; M Ingelman-Sundberg
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

8.  Genetic analysis of the human cytochrome P450 CYP2C9 locus.

Authors:  M J Stubbins; L W Harries; G Smith; M H Tarbit; C R Wolf
Journal:  Pharmacogenetics       Date:  1996-10

9.  Allelic and functional variability of cytochrome P4502C9.

Authors:  C R Bhasker; J O Miners; S Coulter; D J Birkett
Journal:  Pharmacogenetics       Date:  1997-02

10.  Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.

Authors:  A S Aynacioglu; J Brockmöller; S Bauer; C Sachse; P Güzelbey; Z Ongen; M Nacak; I Roots
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

View more
  19 in total

1.  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Authors:  Al-Motassem Yousef; Nailya R Bulatova; William Newman; Nancy Hakooz; Said Ismail; Hisham Qusa; Farah Zahran; Nidaa Anwar Ababneh; Farah Hasan; Imad Zaloom; Ghada Khayat; Rawan Al-Zmili; Randa Naffa; Ola Al-Diab
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

2.  Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.

Authors:  Marcus J P Geist; Gerlinde Egerer; Jürgen Burhenne; Gerd Mikus
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan.

Authors:  Abdoljalal Marjani; Aman Mohammad Gharanjik
Journal:  Indian J Clin Biochem       Date:  2017-05-26

Review 4.  Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors:  Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.

Authors:  Heydy V Bravo-Villalta; Koujirou Yamamoto; Katsunori Nakamura; Ana Bayá; Yuko Okada; Ryuya Horiuchi
Journal:  Eur J Clin Pharmacol       Date:  2005-03-18       Impact factor: 2.953

6.  Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.

Authors:  Mennat-Allah Kamal El-Din; Marwa Salah Farhan; Randa Ibrahim El Shiha; Rania Mohammed Helmy El-Kaffas; Somaia Mohammed Mousa
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

Review 7.  Polymorphism induced sensitivity to warfarin: a review of the literature.

Authors:  Michael P Palkimas; Hillary M Skinner; Pritesh J Gandhi; Alice J Gardner
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

8.  The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery.

Authors:  Maarten J Beinema; Petra H de Jong; Har J M Salden; Merel van Wijnen; Jan van der Meer; Jacobus R B J Brouwers
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.

Authors:  Christoph Markert; Yvonne Schweizer; Regina Hellwig; Theresia Wirsching; Klaus-Dieter Riedel; Juergen Burhenne; Johanna Weiss; Gerd Mikus; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

10.  Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population.

Authors:  Yipeng Ding; Danlei Yang; Long Zhou; Ping He; Jinjian Yao; Pingdong Xie; Daobo Lin; Dingwei Sun; Pei Sun; Quanni Li; Tingting Geng; Tianbo Jin
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.